PBPK modelling to predict drug-biologic interactions with cytokine modulators: Are these relevant and is IL-6 enough?

Kuan-Fu Chen¹, Hannah M. Jones¹, and Katherine L. Gill¹ *

¹Certara UK Limited (Simcyp Division), Sheffield S1 2BJ, UK.

*Corresponding Author
Certara UK Limited (Simcyp Division), Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, UK

t: +44 (0) f: +44 (0)
Email: Kate.Gill@certara.com

Pages: 44
Tables: 4
Figures: 1
References: 94
Word Count:
  Abstract: 227
  Introduction: 447
  Discussion: 4982

Running Title: Cytokine modulated drug interactions

Abbreviations: cytochrome P450 (CYP); drug-biologic interactions (DBIs); the U.S. Food and Drug Administration (FDA); drug-drug interactions (DDIs); interleukin (IL); Physiologically-based pharmacokinetic (PBPK); rheumatoid arthritis (RA); maximum fold suppression (Eₘᵣᵢₙ); concentration that supports half-maximal suppression (EC₅₀); interferon (IFN); ethoxyresorufin-O-deethylase (EROD); tumor necrosis factor (TNF); vascular endothelial growth factor (VEGF); area under the curve (AUC); oral clearance (CL_po); human immunodeficiency virus (HIV); monoclonal antibodies (mAb); IL-2 receptor α (IL-2Rα); P-glycoprotein (P-gp); toll-like receptor (TLR); peak concentration (C_max); C-reactive protein (CRP)
Abstract

Drugs that modulate cytokine levels are often used for the treatment of cancer as well as inflammatory or immunological disorders. Pharmacokinetic drug-biologic interactions (DBI) may arise from suppression or elevation of cytochrome P450 (CYP) enzymes caused by the increase or decrease in cytokine levels following administration of these therapies. There is in vitro and in vivo evidence that demonstrates a clear link between raised interleukin (IL)-6 levels and CYP suppression, in particular CYP3A4. However despite this, the changes in IL-6 levels in vivo rarely lead to significant drug interactions (AUC and C_max ratios < 2-fold). The clinical significance of such interactions therefore remains questionable and is dependent on the therapeutic index of the small molecule therapy. Physiologically-based pharmacokinetic (PBPK) modelling has been used successfully to predict the impact of raised IL-6 on CYP activities. Beyond IL-6, published data show little evidence that IL-8, IL-10, and IL-17 suppress CYP enzymes. In vitro data suggest that IL-1β, IL-2, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ can cause suppression of CYP enzymes. Despite in vivo there being a link between IL-6 levels and CYP suppression, the evidence to support a direct effect of IL-2, IL-8, IL-10, IL-17, IFN-γ, TNF-α or vascular endothelial growth factor (VEGF) on CYP activity is inconclusive. This commentary will discuss the relevance of such drug-biologic interactions and whether current PBPK models considering only IL-6 are sufficient.
Significance Statement

This commentary summarizes the current in vitro and in vivo literature regarding cytokine-mediated CYP suppression and compares the relative suppressive potential of different cytokines in reference to IL-6. It also discusses the relevance of drug-biologic interactions to therapeutic use of small molecule drugs and whether current PBPK models considering only IL-6 are sufficient to predict the extent of drug-biologic interactions.
Introduction

Biologic drugs have been used or tested in combination with small molecule drugs for the treatment of immunological diseases, such as inflammatory bowel disease and rheumatoid arthritis (Paramsothy et al., 2018; Dolinger et al., 2021; Genovese et al., 2008), and oncologic disorders, such as leukemia, breast cancer, gastrointestinal stromal tumors and colorectal cancer (Sharman et al., 2019; Canoici et al., 2019; Vallilas et al., 2021; Poindessous et al., 2011). Many of these biologics modulate cytokine levels. An increase or decrease in cytokines levels has been shown to suppress or elevate cytochrome P450 (CYP) enzymes (Abdel-Razzak et al., 1993, 1994; Aitken and Morgan, 2007; Dallas et al., 2012; Donato et al., 1993, 1997; Guillén et al., 1998; Sunman et al., 2004; Dickmann et al., 2012; Li et al., 2014; Mimura et al., 2015; Rubin et al., 2015; Klein et al., 2015). CYP enzymes are an important class of enzymes responsible for the metabolism of many small molecule drugs (Wienkers and Heath, 2005; Zanger and Schwab, 2013). Thus, pharmacokinetic drug-biologic interactions (DBIs) may arise following co-administration of small molecules and biologics. For therapeutic proteins acting as cytokine modulators, the U.S. Food and Drug Administration (FDA) requires language in the label to indicate whether there is a potential for drug-drug interactions (DDIs) (FDA Draft Guidance, 2020).

Despite the clear *in vitro* and *in vivo* links between interleukin (IL)-6 levels and CYP suppression and in particular CYP3A4, the changes in IL-6 levels *in vivo* rarely lead to significant drug interactions (i.e., < 2-fold; Morgan et al., 2008; Harvey and Morgan, 2014; Coutant & Hall, 2018). Physiologically-based pharmacokinetic (PBPK) modeling has been used successfully to predict the impact of raised IL-6 on CYP activities (Machavaram et al., 2013, 2019; Jiang et al., 2016; Xu et al., 2015; Stader et al., 2021; Lenoir et al., 2021). Beyond IL-6,
evidence to support a direct effect of other cytokines on CYP activity remains inconclusive. The underlying mechanisms of CYP modulation can be cytokine-specific (de Jong et al., 2020), potentially leading to synergistic effects. The effect of combining cytokines has been assessed in vitro (Dickmann et al., 2012; Xu et al., 2015), however, PBPK simulation to evaluate the impact of other cytokines on drug exposures has not been performed. This commentary summarizes the current literature regarding cytokine-mediated CYP suppression and compares the relative suppressive potential of different cytokines in reference to IL-6. Subsequently, the relevance of such DBIs and whether current PBPK models considering only IL-6 are sufficient are discussed. Cytokines can also affect other enzymes and transporters (Lévesque et al., 1998; Richardson et al., 2006; Le Vée et al., 2009; Fardel and Le Vée, 2009), but this commentary will focus on their effect on CYPs.
Evidence of Cytokine Suppression of CYP Enzymes In Vitro

In vitro CYP suppression by IL-6

The majority of the available in vitro data focus on IL-6. Of the cytokines tested in vitro, IL-6 generally causes the greatest CYP suppression, with CYP3A4 being the most sensitive isoform (Abdel-Razzak et al., 1993, 1994; Aitken and Morgan, 2007; Dallas et al., 2012; Donato et al., 1993, 1997; Guillén et al., 1998; Sunman et al., 2004; Dickmann et al., 2012; Li et al., 2014; Mimura et al., 2015; Rubin et al., 2015; Klein et al., 2015). Decreases in CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 activity/mRNA/protein abundance of up to 36, 78, 72, 54, 88, 39, 50 and 98% have been reported, although suppression of CYP1A2 often did not reach statistical significance (Abdel-Razzak et al., 1993, 1994; Aitken and Morgan, 2007; Dallas et al., 2012; Donato et al., 1993, 1997; Guillén et al., 1998; Sunman et al., 2004). These studies usually measure the effect of cytokines at a single concentration that is far in excess of those seen in diseases or following administration of immune modulators. For example, IL-6 concentrations of 0.5 – 200 ng/mL have been used in vitro, whereas mean values in rheumatoid arthritis (RA) patients and post-surgery are 54 and 229 pg/mL, respectively (Machavaram et al., 2013). Another meta-analysis comprising 11,583 cancer patients reported a median IL-6 serum level of 6.95 pg/mL (range: 0.23 – 78.5 pg/mL) compared to the control level of 1.31 pg/mL (range: 0 – 37 pg/mL) (Lippitz and Harris, 2016). A mean serum peak IL-6 concentration of 4400 pg/mL was observed after initiation of blinatumomab (up to 90 µg/m²/day) in patients with acute lymphoblastic leukemia (Xu et al., 2015), which is still lower than IL-6 concentrations used in most in vitro assays.

In the Dickmann et al. (2011) in vitro study, cryopreserved and fresh human hepatocytes were used to determine the suppression of several CYPs by IL-6 over a range of concentrations
(0.5 – 10,000 pg/mL) which are more relevant to those observed in disease states or following administration of immune modulators. The IL-6 concentration that supports half-maximal suppression (EC$_{50}$) and maximum fold suppression (E$_{min}$) values for CYP mRNA and for CYP1A2 and CYP3A4 activity were reported (Table 4). IL-6 EC$_{50}$ values are generally in excess of IL-6 levels observed in RA patients, with the exception of CYP3A4 (EC$_{50}$ = 3.23 pg/mL CYP3A4 for mRNA; mean EC$_{50}$ (range) = 73.2 (4.23 – 176) pg/mL for CYP3A4 activity) (Dickmann et al., 2011). Significant CYP suppression is unlikely if IL-6 concentration is below EC$_{50}$ values, although IL-6 concentration can be transiently elevated to a much higher level following administration of cytokine modulators.

Evers et al. (2013) studied between-laboratory variability in IL-6 suppression of CYP3A4 by incubating hepatocytes from the same donor at 6 different laboratories for 48 h with 0.001 – 500 ng/mL IL-6. Despite high between-laboratory variability, the reported CYP3A4 activity E$_{min}$ values (0.20 – 0.38 in the absence of dexamethasone) are consistent with those reported in Dickmann et al. (2011). Similarly, the CYP3A4 activity EC$_{50}$ value reported by Evers et al. (2013) (217 pg/mL in the absence of dexamethasone) is close to the upper limit of the range of values for individual hepatocyte donors reported by Dickmann et al. (2011). Contrarily, the CYP3A4 mRNA EC$_{50}$ value reported by Dickmann et al. (2011) is about 30-fold lower than the value reported by Evers et al. (2013) (94.7 pg/mL in the absence dexamethasone).

In vitro CYP suppression by other cytokines

Suppression of CYPs by IL-2 has been measured in vitro in two studies (Dallas et al., 2012; Sunman et al., 2004). Dallas et al. (2012) reported that IL-2 did not have a statistically significant effect on CYP1A2, CYP2C9 or CYP3A4 mRNA or activity in cryopreserved hepatocytes incubated with 10 ng/mL IL-2 for 48 h. Modest but significant suppression (< 25%)
of CYP2B6 and CYP2C19 (activity only) were observed (Table 1). CYP2D6 mRNA was increased by 50%, whereas CYP2D6 activity was decreased by 22% (Table 1). Comparison to the CYP activity and mRNA suppression by IL-6 in the same *in vitro* assay as represented by the ratios of % decrease relative to IL-6, shows that IL-2 has less of a suppressive action when compared to IL-6 (Table 1). Sunman *et al.* (2004) reported no suppression of CYP3A activity by IL-2 (2 – 200 ng/mL) in hepatocyte cultures but a concentration-dependent 50 – 70% suppression in hepatocyte/Kupffer cell co-cultures. This suggests that IL-2 acts via an indirect mechanism, probably through stimulating Kupffer cells to produce other cytokines such as IL-6.

Suppression of CYPs by interferon (IFN)-γ has been measured *in vitro* in 6 studies (Abdel-Razzak *et al.*, 1993, 1994; Aitken and Morgan *et al.*, 2007; Donato *et al.*, 1993, 1997; Guillén *et al.*, 1998). Abdel-Razzak *et al.* (1993) reported that IFN-γ did not change CYP2C or CYP3A mRNA in fresh hepatocytes incubated with 50 U/mL IFN-γ for 72 h. In contrast, 21 to 55% decrease in nifedipine activity (CYP3A substrate) was found in 2 donors. A marked reduction in CYP1A2 and CYP2E1 mRNA was observed in 2 of 3 donors and ethoxyresorufin-O-deethylase (EROD) activity was reduced by 29 – 53% in 6 donors (Table 2). Similarly, in a follow up study, EROD activity was significantly reduced by 22 – 42% in 4 fresh hepatocyte donors incubated with 50 U/mL IFN-γ for 72 h (Table 2) (Abdel-Razzak *et al.*, 1994). Aitken and Morgan (2007) reported that incubation of fresh hepatocytes with 10 ng/mL IFN-γ for 24 h led to a statistically significant decrease in CYP2C8, CYP3A4 and CYP2B6 mRNA and protein expression of CYP3A4 and CYP2B6 (Table 2). IFN-γ did not have a statistically significant effect on CYP2C9, CYP2C18 or CYP2C19 mRNA; however, a significant decrease in CYP2C9 protein expression was observed after 24 h in 1 donor (Aitken and Morgan, 2007). Guillén *et al.* (1998) reported that IFN-γ reduced CYP1A2, CYP2B6, CYP2A6 and CYP3A4 activity in fresh
hepatocytes incubated with 300 U/mL IFN-γ for 48 h (Table 2). Comparison of the CYP activity, protein expression or mRNA suppression caused by IFN-γ to that caused by IL-6 in the corresponding studies shows that IFN-γ generally has a similar or reduced suppressive action when compared to IL-6, with the exception of CYP1A2 activity where IFN-γ is a more potent suppressor (Table 2).

There are no reported E\textsubscript{min} and EC\textsubscript{50} values describing the IFN-γ suppression of CYPs and the majority of the \textit{in vitro} data have been measured at a single IFN-γ concentration. However, concentration dependent suppression of CYP1A2 activity has been reported, allowing the calculation of E\textsubscript{min} and EC\textsubscript{50} values for IFN-γ (Donato \textit{et al.}, 1993, 1997; Guillén, 1998). The calculated IFN-γ E\textsubscript{min} and EC\textsubscript{50} values are 0.629 and 2460 pg/mL (measured at 500 – 150000 pg/mL in Donato \textit{et al.}, 1993), 0.572 and 4400 pg/mL (measured at 1500 – 50000 pg/mL in Donato \textit{et al.}, 1997) and 0.601 and 4098 pg/mL (measured at 2500 – 50000 pg/mL in Guillén \textit{et al.}, 1998), respectively (Table 4). Comparing these values to those for IL-6 (mean E\textsubscript{min} (range) = 0.230 (0.0622 – 0.529) and mean EC\textsubscript{50} (range) = 1251 (142 - 4070) pg/mL) (Table 4; Dickmann \textit{et al.}, 2011) suggests IFN-γ is not as potent a CYP1A2 suppressor as IL-6. It should be noted that the IFN-γ concentrations used \textit{in vitro} are far in excess of physiological concentrations in healthy subjects (7.5 – 21.2 pg/mL or 0.3 ± 0.1 U/mL) and those with RA (17.9 – 32.6 pg/mL), acute respiratory infections (3.4 ± 1.3 U/mL) (Brockmeyer \textit{et al.}, 1992; Caris \textit{et al.}, 2020) or acute lymphoblastic leukemia following blinatumomab administration (peak ~ 440 pg/mL) (Xu \textit{et al.}, 2015).

Suppression of CYPs by tumor necrosis factor (TNF)-α has been measured \textit{in vitro} in 5 studies (Abdel-Razzak \textit{et al.}, 1993; Aitken and Morgan, 2007; Dallas \textit{et al.}, 2012, Mimura \textit{et al.}, 2015; Klein \textit{et al.}, 2015). Abdel-Razzak \textit{et al.} (1993) reported that TNF-α decreased CYP1A2,
CYP2C, CYP2E1, and CYP3A mRNA levels by 30% – 80% in all 3 donors after 72-hour incubation (Table 3). EROD and nifedipine oxidation activities were also decreased by 32 – 85% and 24 – 90%, suggesting reduced CYP1A2 and CYP3A4 activities. Similarly, Aitken and Morgan (2007) reported significant reduction in CYP2C8 (but not CYP2C9) and CYP3A4 mRNA levels (n = 9). Additionally, they quantified CYP2B6, CYP2C9, and CYP3A4 protein levels using western blotting and found that TNF-α treatment significantly reduced CYP2B6 and CYP2C9 proteins by 87% and 94%, respectively (Table 3). The CYP3A4 protein level decreased in a similar trend but statistical significance was not detected. Dallas et al. (2012) measured mRNA levels and enzyme activities for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Following TNF-α treatment, reduction in CYP1A2, CYP2D6, and CYP3A4 mRNA levels were detected (Table 3). TNF-α also reduced CYP3A4 mRNA by 51% in Hepatoma cell line FLC-4 over a 24-hour incubation, although TNF-α had no effect on CYP3A4 protein expression or activity (Mimura et al., 2015). Reduction in enzyme activities were significant in all CYP isoforms tested and generally comparable to reduction caused by IL-6, except for CYP1A2 where a greater reduction was observed following TNF-α treatment compared to IL-6 treatment (Table 3).

Klein et al. (2015) proposed HepaRG cells as a surrogate for primary human hepatocytes and, using HepaRG cells, characterized dose-response curves for CYP1A2, CYP2B6, CYP2C9, and CYP3A4 by measuring mRNA levels in a range of TNF-α concentrations (0.1 – 50000 pg/mL). Using data from this study, the $E_{\text{min}}$ and $EC_{50}$ values of TNF-α for CYP1A2 (0.0337 and 817 pg/mL), CYP2B6 (0.639 and 86.6 pg/mL), CYP2C9 (0.289 and 153 pg/mL) and CYP3A4 (0.107 and 133 pg/mL) were determined (Table 4), suggesting weaker suppression for CYPs compared to IL-6 except CYP1A2. Despite a stronger effect in CYP1A2 suppression compared
to IL-6 (Table 4), it should be noted that TNF-α EC$_{50}$ values were in excess of concentrations observed in patients with immunological diseases (e.g., 30.5 pg/mL in RA patients with chronic periodontitis vs. 5.5 pg/mL in control (Thilagar et al., 2018) and 25.7 pg/mL in psoriatic patients vs. 11.2 pg/mL in control (Arican et al., 2005)), although within the range of TNF-α concentrations observed following administration of cytokine modulators (e.g., peak ~ 200 pg/mL in acute lymphoblastic leukemia patients given blinatumomab (Xu et al., 2015)).

*In vitro* data for other cytokines are limited. Currently there are no *in vitro* data available in the public domain regarding CYP suppression by IL-8, IL-17 and vascular endothelial growth factor (VEGF). Xu et al. (2015) indicate that *in vitro* studies in human hepatocytes revealed no effect of IL-10 on CYP enzymes even at 5000 pg/mL. The studies were conducted internally by Amgen Inc.; however, the data were not reported in the publication (Xu et al., 2015).

Although multiple cytokines are raised simultaneously in disease states and following dosing of certain cytokine modulator biologic drugs *in vivo*, the majority of *in vitro* studies have assessed the CYP suppression caused by one cytokine alone rather than the effect of a combination of cytokines. Underlying mechanisms of CYP suppression are cytokine-specific, hence synergistic effects on CYP modulation are possible. The pre- and post-transcriptional mechanistic pathways, such as transcriptional factor regulation and nitric oxide stimulation, were previously discussed (de Jong et al., 2020). However, *in vitro* data to confirm or refute cytokine synergism are limited. In the Dickmann et al. (2012) *in vitro* study, cryopreserved and fresh human hepatocytes from 1 donor were used to determine the suppression of several CYPs by IL-1β alone or in combination with IL-6 over a range of physiologically relevant concentrations (10 and 100 pg/mL IL-1β and IL-6). Dickmann et al. reported IL-1β alone was 6-fold less potent than IL-6 (based upon EC$_{50}$ values) for suppression of CYP3A4. The combination of IL-1β and
IL-6 did not increase the CYP suppression caused by IL-6 alone for CYP1A2 and CYP2C9. The combination of 100 pg/mL IL-1β with IL-6 reduced the suppression of CYP2B6 caused by 100 pg/mL IL-6 alone. In contrast, the combination of 100 pg/mL IL-1β and IL-6 had an additive down regulation on CYP3A4 mRNA and activity compared to IL-6 alone, reducing CYP3A4 mRNA/activity to 26% versus 37% of control values, respectively.

Xu et al. (2015) also studied the suppression of multiple CYPs in 3 hepatocyte donors when incubated with a cocktail of cytokines (IL-2, IL-6, IL-10, IFN-γ and TNF-α). Three concentrations of cytokines were used, based on the low (125 pg/mL for all cytokines), mid (2000 pg/mL IL-6, IL-10 and IFN-γ with 500 pg/mL for IL-2 and TNF-α) and high (20000 pg/mL IL-6, IL-10 and IFN-γ with 1000 pg/mL for IL-2 and TNF-α) levels of cytokines observed following dosing of blinatumomab (0.5 to 90 µg/m²/day) to non-Hodgkin Lymphoma patients. Similar CYP suppression was observed with the mid and high concentration cytokine cocktails, indicating the suppression is maximized by the mid-strength cytokine levels (Xu et al., 2015). Limited suppression was observed in most donors for CYP2C19 and CYP2D6 activity, even with high cytokine levels, whereas > 50% suppression of CYP1A2, CYP2C9 and CYP3A4 activity was observed in 2 or 3 donors with the highest cytokine levels. The level of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 suppression observed with mid or high strength cytokine cocktails by Xu et al. (2015) was within the range of values reported by other in vitro studies using IL-6, TNF-α or IFN-γ alone (Abdel-Razzak et al., 1993, 1994; Aitken and Morgan, 2007; Dallas et al., 2012; Donato et al., 1993, 1997; Sunman et al., 2004; Dickmann et al., 2012). This suggests that suppression by combinations of cytokines is not likely to increase the extent of CYP suppression compared to incubation with a single cytokine.
Evidence of Cytokine Suppression of CYP Enzymes In Vivo

Changes in circulating cytokine levels have been linked to alterations in drug metabolism in vivo (Harvey and Morgan, 2014; Morgan et al., 2008). There are several reports of alteration of CYP substrate PK in disease/infection/following vaccination where there is an inflammatory response and hence increase in circulating cytokine levels. In addition, DDIs between CYP substrates and biologic drugs that are themselves cytokines or cytokine modulators have been reported (Evers et al., 2013; Huang et al., 2010; Lee et al., 2010).

In vivo CYP suppression by IL-6

The correlations between raised IL-6 concentrations and CYP activity have been reviewed previously (Morgan et al., 2008; Harvey and Morgan, 2014; Coutant & Hall, 2018). A few examples are detailed here. Raised IL-6 concentrations have been significantly correlated with decreased CYP1A2, CYP2C9, CYP2C19 and CYP3A4 activity in congestive heart failure, cancer, bone marrow transplant, COVID-19 infection and surgery patients (Frye et al., 2002; Lenoir et al., 2021a; Sato et al., 2016; Trousil et al., 2019; Chen et al., 1994; Lenoir et al., 2021b). In contrast, raised IL-6 concentrations were associated with increased CYP2E1 activity in ovarian cancer patients and CYP2C9 activity in hip surgery patients (Trousil et al., 2019; Lenoir et al., 2021b). However, CYP2D6 activity did not change in hip surgery patients within 3 days of surgery or in COVID-19 infected patients (Lenoir et al., 2021a; Lenoir et al., 2021b).

Several therapeutic protein-drug interactions relating to IL-6 have also been reported. Administration of sarilumab or tocilizumab to RA patients led to a decrease in simvastatin, midazolam, omeprazole and S-warfarin area under the curve (AUC), a slight increase in CYP1A2 AUC and no effect on CYP2D6 activity (Lee et al., 2017; Schmitt et al., 2011; Zhuang et al., 2015; Zhang et al., 2009; Terao et al., 2010). Similarly, COVID-19 infected patients who...
received tocilizumab > 12 hours prior to lopinavir administration had significantly lower lopinavir (CYP3A4 substrate) exposure (Marzolini et al., 2020). Sarilumab and tocilizumab are monoclonal antibodies (mAbs) that block IL-6 from binding to its receptor and hence remove the suppressive effect of raised IL-6 on CYPs in RA and COVID-19 patients, leading to increased CYP activity and co-administered drug clearance.

In vivo CYP suppression by other cytokines

CYP1A2, CYP2C, CYP2E1 and CYP3A protein expression was reduced to 37, 45, 60 and 39% of control values in hepatic microsomes isolated from surgical samples from hepatectomy patients receiving high doses of IL-2 (9 or 12 x 10^6 U/m^2) prior to surgery (Elkahwaji et al., 1999). Similarly, methoxyresorufin and erythromycin activity was significantly reduced following IL-2 administration (Elkahwaji et al., 1999). Indinavir trough concentrations and AUC significantly increased with a corresponding significant decrease in oral clearance (CLpo) following administration of IL-2 (Proleukin) in human immunodeficiency virus (HIV) patients (Piscitelli et al., 1998). However, significant increases in IL-6 concentration were also observed over the 5-day IL-2 infusion, with mean IL-6 concentrations of ~ 80 pg/mL by Day 5 (Piscitelli et al., 1998). These levels of IL-6 are similar to those observed in RA patients (Machavaram et al., 2013), where administration of IL-6R antagonists tocilizumab and sirukumab led to a 2.4- and 1.5-fold decrease in AUC of CYP3A4 substrates simvastatin and midazolam (Schmitt et al., 2011; Zhuang et al., 2015). Thus, the similar level of interaction (AUC ratio 1.9-fold) between Proleukin and indinavir (CYP3A4 substrate) suggests that IL-2 does not cause an increased suppression of CYP3A4 compared to that caused by IL-6 alone.

Basiliximab and daclizumab are monoclonal antibodies (mAb) that act as IL-2 receptor α (IL-2Rα) antagonists. Following administration of IL-2Rα antagonists (mainly basiliximab) to
renal transplant patients, tacrolimus trough concentrations significantly increased (Sifontis et al., 2002; Lin et al., 2015). Similarly, significantly increased cyclosporine trough concentrations, early cyclosporine toxicity and a lower dose requirement were found in pediatric renal transplant patients following dosing with basiliximab when compared to controls (Strehlau et al., 2000). The reduction in tacrolimus and cyclosporine clearance is thought to be due to basiliximab blocking the binding of circulating IL-2 to IL-2Rα on T cells and instead IL-2 binds to the IL-2R on hepatic and intestinal cells leading to suppression of CYP3A4 (Sifontis et al., 2002). In contrast, administration of daclizumab to multiple sclerosis patients had no effect on the exposure of midazolam, S-warfarin, omeprazole, caffeine or dextromethorphan (Tran et al., 2016). IL-6 concentrations were not monitored in these studies.

There are few reports linking IL-8 to suppression of CYP metabolism in vivo and no data following direct dosing of IL-8 or IL-8 antagonists. In psoriasis patients, IL-8 concentrations were significantly increased (~ 10 pg/mL) when compared to healthy subjects; however, no correlation was found between raised IL-8 levels and venlafaxine (CYP2D6 and P-glycoprotein (P-gp) substrate) metabolic ratios (Godoy et al., 2016). In contrast, raised IL-8 levels in ovarian cancer patients (71.6 pg/mL) were significantly associated with increased CYP2E1 activity (3-fold) and reduced CYP3A4 activity (42%) when compared to healthy volunteers (Trousil et al., 2019). However, the changes in enzyme activity were also significantly associated with IL-6 and TNF-α levels. In fact, the IL-6 concentration (37.3 pg/mL) and the extent of reduction in CYP3A4 activity in ovarian cancer patients were comparable to those in RA patients before sirukumab treatment (Zhuang et al., 2015). Since IL-8, TNF-α and IL-6 could all contribute to effects in CYP2E1 and CYP3A4 activity, a direct role of IL-8 in a CYP2E1 or CYP3A4-mediated DDIs is inconclusive.
A double-blind crossover study where 8 µg/kg of IL-10 and placebo were administered to healthy volunteers once-daily for 6 days has been published (Gorski et al., 2000). On Days 4 and 5, tolbutamide (CYP2C9), caffeine (CYP1A2), dextromethorphan (CYP2D6), and midazolam (CYP3A4) were co-administered. The study showed that administration of IL-10 did not alter CYP1A2, CYP2C9, and CYP2D6 activities, and the CYP3A activity was reduced by only 12% ± 17%. The IL-10 concentrations following dosing of 8 µg/kg are likely to be much higher than those observed in patients with immune disorders (89.5 pg/mL in psoriasis, 58.7 pg/mL in RA and 12.6 pg/mL in systemic lupus erythematosus) (Sobhan et al., 2016; Lacki et al., 1995; Godsell et al., 2016).

There are few reports linking IFN-γ to suppression of CYP metabolism in vivo and there are no data following direct dosing of IFN-γ or IFN-γ antagonists. In healthy subjects suffering with an acute viral respiratory infection, IFN-α and IFN-γ concentrations were significantly increased (2.7- and 11.3-fold, respectively), and antipyrine clearance significantly decreased (1.3-fold) compared to controls (Brockmeyer et al., 1992). IFN-α and IFN-γ concentrations are also markedly higher in HIV patients with severe disease. When these patients were treated with zidovudine, the IFN-α and IFN-γ concentrations significantly decreased (60 and 59%, respectively) and antipyrine clearance significantly increased (1.2-fold) (Brockmeyer et al., 1992, 1998). Decreases in theophylline, antipyrine, caffeine, mephenytoin, debrisoquine, chlorzoxazone, and erythromycin metabolism have been reported following direct administration of INF-α to hepatitis and melanoma patients, as reviewed by Lee et al. (2010). Therefore, the CYP suppression observed in respiratory infection and HIV patients may be due to increased IFN-α rather than IFN-γ. Other cytokines such as IL-6 may also be increased in these diseases. Changes in antipyrine clearance in subjects with respiratory infection or in HIV patients treated...
with zidovudine are generally more limited than the changes in CYP substrate clearance reported upon administration of IL-6R antagonists to RA patients (Schmitt et al., 2011; Zhuang et al., 2015).

There have been several reports of vaccine-drug interactions, which have been attributed to increases in IFN-γ concentrations following vaccination (Pellegrino et al., 2015). The data for warfarin (CYP2C9) are conflicting between studies, which may reflect the limited effect of IFN-γ on CYP2C9 in vitro (Aitken and Morgan, 2007). Reports for theophylline (CYP1A2) are also conflicting (Pellegrino et al., 2015; Jonkman and Upton, 1984), potentially due to inappropriate timing of some studies, whereby the maximum CYP suppression and effect on theophylline PK were missed due to the sparse sampling used. There are limited reports of vaccine interactions with anticonvulsants (e.g. carbamazepine, phenytoin, phenobarbital) showing an increase in anticonvulsant exposure following vaccination, although the extent and duration of the drug-vaccine interaction differs widely between reports (Pellegrino et al., 2015). Vaccination also causes a significant transient increase in IL-6 and other cytokine concentrations (Herrin et al., 2014; Kuhlman et al., 2018; Tsai et al., 2005; Sharpley et al., 2016; Brydon et al., 2008; Harrison et al., 2009; Wright et al., 2005). Therefore, the role of IFN-γ in drug-vaccine interactions is not clear.

Frye et al. (2002) reported that, in congestive heart failure patients given a metabolic probe cocktail consisting of caffeine (CYP1A2), mephenytoin (CYP2C19), dextromethorphan (CYP2D6), and chloroxazone (CYP2E1), a significant inverse relationship was found between both TNF-α and IL-6 plasma concentrations and the activity of CYP2C19. Since both TNF-α and IL-6 could contribute to suppression of CYP2C19 activity, the role of TNF-α in a CYP2C19-mediated DDI is inconclusive. In another study, HIV patients had lower CYP3A4 and CYP2D6
activity when compared to age and sex matched healthy volunteers (18% and 90%, respectively) but no significant difference for CYP1A2 (Jones et al., 2010). Higher TNF-α concentrations in HIV patients were significantly correlated with the reduced CYP3A4 activity but not CYP2D6 activity (Jones et al., 2010). Raised TNF-α levels in ovarian cancer patients (45.4 pg/mL) were significantly associated with increased CYP2E1 activity (3-fold) and reduced CYP3A4 activity (42%) when compared to healthy volunteers (Trousil et al., 2019). However, the changes in enzyme activity were also significantly associated with IL-6 and IL-8 levels. Since IL-8, TNF-α and IL-6 could all contribute to effects on CYP2E1 and CYP3A4 activity, the role of TNF-α in a CYP2E1 or CYP3A4-mediated DDI is inconclusive. In psoriasis patients, TNF-α concentrations were also significantly increased (~12 pg/mL) when compared to healthy subjects; however, no correlation was found between raised TNF-α levels and venlafaxine (CYP2D6 and P-gp substrate) metabolic ratios (Godoy et al., 2016). Similarly, TNF-α levels in patients infected with COVID-19 or following hip surgery did not correlate with the decreased CYP1A2, CYP2C19 or CYP3A4 activity observed in these patients, which is likely due to the increased IL-6 levels (Lenoir et al., 2021a; Lenoir et al., 2021b).

A few therapeutic protein-drug interactions relating to TNF-α have also been reported. Etanercept is a fusion protein that blocks TNF-α from binding to its receptor and hence would remove any suppressive effect of raised TNF-α on CYPs in patients. Administration of etanercept to healthy volunteers had no effect on digoxin (P-gp substrate) or warfarin (CYP2C9 substrate) exposure (Zhou et al., 2004a; Zhou et al., 2004b); however, healthy volunteers would be expected to have low circulating TNF-α levels and hence any potential CYP suppression prior to etanercept administration would be minimal. Wen et al. (2020) reported a case study of a patient with ankylosing spondylitis, hypertension, diabetes mellitus and IgA nephropathy who
was receiving etanercept and cyclosporine. Use of etanercept was correlated with increased cyclosporine (CYP3A4 substrate) clearance; however the authors suggest this was due to the large decrease in circulating IL-2 concentrations following administration of etanercept, rather than a direct effect of TNF-α on CYP3A4 (Wen et al., 2020).

*In vivo* data regarding CYP suppression by VEGF and IL-17 are extremely limited. In one Phase I/II clinical trial, bevacizumab (anti-VEGF mAb) was administered to non-small-cell lung cancer patients with erlotinib (CYP3A4 substrate) and exposure of both drugs was compared to that in patients receiving each drug alone (Herbst et al., 2005). No differences in erlotinib PK were found upon co-administration of bevacizumab, suggesting that VEGF does not have a suppressive effect on CYP3A4. In psoriasis patients, IL-17 concentrations were significantly increased (~ 4 pg/mL) when compared to healthy subjects; however, no correlation was found between raised IL-17 levels and venlafaxine (CYP2D6 substrate and P-gp) metabolic ratios (Godoy et al., 2016).

Finally, it is worth noting the cytokine modulatory effects of some small molecule drugs e.g. toll-like receptor (TLR)-7 agonists. Jones et al. (2012) hypothesized that the time dependent PK observed for PF-04878691 was as a result of CYP suppression caused by TLR-7 agonism causing elevation of cytokine levels. This example illustrates that cytokine-mediated DDIs are not limited to biologics only, as small molecules that alter cytokine levels can also lead to modulation of CYP expression.

**PBPK Modeling of Cytokine Suppression of CYP Enzymes**
Data for the in vitro suppression of CYP activity or mRNA from Dickmann et al. (2011) have been used to successfully describe the clinical consequences of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 suppression by IL-6 in PBPK models (Machavaram et al., 2013, 2019; Jiang et al., 2016; Xu et al., 2015; Stader et al., 2021; Lenoir et al., 2021c). The former three models are designed to capture the therapeutic protein-drug interactions in patients who have chronically raised IL-6 levels (Machavaram et al., 2013, 2019; Jiang et al., 2016). Even at the highest IL-6 concentration tested (100 pg/mL) by Machavaram et al. (2019), only small suppression of CYP2C9 and CYP2D6 (37.7 and 26.8% reduction in enzyme levels, respectively) and weak DDIs with S-warfarin and dextromethorphan (AUC ratios = 1.33 and 1.36, respectively) were predicted. No interaction was predicted for the CYP1A2 substrate caffeine. Suppression of CYP2C19 and CYP3A4 was moderate (46 and 43% reduction in enzyme levels, respectively) and moderate DDIs were predicted with CYP3A4 substrates (AUC ratios = 2.30 and 2.07 for simvastatin and midazolam, respectively). The predicted and observed AUC and peak concentration (C_max) ratios in the presence and absence of chronically elevated IL-6 are summarized in Figure 1.

In contrast, the models published in Xu et al. (2015), Stader et al. (2021) and Lenoir et al. (2021) focus on transiently raised IL-6 levels. IL-6 levels increased rapidly to a mean peak of ~1600 pg/mL (60,000 pg/mL in the subject with the highest levels) at 6 h post blinatumomab administration and then decreased to baseline by 48 h (Xu et al., 2015). The maximum predicted suppression of CYP3A4, CYP1A2 and CYP2C9 was 28, 9 and 17%, occurring at 48, 48 and 70 h post blinatumomab administration, respectively (Xu et al., 2015). Predicted CYP3A4 and CYP1A2 levels had returned to baseline by 1 week and CYP2C9 by 9 days post blinatumomab administration (Xu et al., 2015). Weak interactions were predicted for CYP3A4 substrates
simvastatin and midazolam (AUC ratios = 1.9 and 1.7, respectively), whereas no interaction (AUC ratio < 1.25-fold) was predicted for CYP1A2 substrates theophylline and caffeine or CYP2C9 substrate S-warfarin when dosed 48 h after blinatumomab (Xu et al., 2015). IL-2, IL-10, IFN-γ and TNF-α were also significantly raised following blinatumomab dosing (peak ~ 170, 2400, 440 and 200 pg/mL, respectively, at the highest blinatumomab dose level). However, these cytokines were not included within the PBPK model due to the lack of in vivo data showing a meaningful effect of IL-10 or a direct effect of IL-2, IFN-γ and TNF-α on CYP activity. The predicted AUC and C_{max} ratios in the presence and absence of transiently elevated IL-6 are also summarized in Figure 1.

Similarly, Stader et al. (2021) considered the effects of higher IL-6 concentrations (1 – 50,000 pg/mL) observed in COVID-19 patients; however, only a weak interaction with CYP3A4 substrate midazolam (AUC ratio = 1.33) was predicted even at the highest IL-6 concentration. Lenoir et al. (2022) recovered the concentrations of omeprazole and 5-OH-omeprazole in subjects before and after hip-surgery by incorporating the combinatorial effects of elevated IL-6 (peak ~ 50 pg/mL at 24 h post-surgery) and co-administration of esomeprazole (a mechanism-based inhibitor for CYP2C19). It is likely that reduction in CYP2C19 activity was due mostly to inhibition by esomeprazole and minimally to suppression by IL-6, but this was not confirmed using the model in the paper.

In comparison to the PBPK models described above, a recent publication has used a top down fitting approach with a PBPK model to predict the effect of inflammation on CYP2C19 and CYP3A4 suppression (Simon et al., 2021). Instead of modeling IL-6, C-reactive protein (CRP) concentrations were related to CYP2C19 and CYP3A4 activity using an empirical model fitted to clinical data, and the resultant in vivo parameters for downregulation of CYP activities...
were integrated into a PBPK model (Simon et al., 2021). The recovery of midazolam, voriconazole and omeprazole concentrations in patients with a mean CRP of 25.3 mg/L vs. 0.5 mg/L suggest that the activity of CYP2C19 and CYP3A4 can be predicted using CRP concentration. The production of CRP is stimulated by IL-6, thus they are highly correlated in diseases (Del Giudice and Gangestad, 2018).
Conclusions and current knowledge gaps

Raised cytokine levels have been linked to suppression of CYP enzymes both in vitro and in vivo (Evers et al., 2013; Huang et al., 2010; Lee et al., 2010; Harvey and Morgan, 2014; Morgan et al., 2008, Gorski et al., 2000; Aitken and Morgan, 2007; Klein et al., 2015; Dallas et al., 2012). In vitro data suggest that IL-6 is the most potent suppressor of the majority of CYPs and CYP3A4 is the most sensitive CYP enzyme (Tables 1-3). Compared to IL-6, IFN-γ and TNF-α appear to have a reduced or similar suppressive effect, although they may cause greater suppression of CYP1A2. IL-2 and IL-1β CYP suppression is minor and IL-10 does not cause CYP suppression even at high concentrations. Incubation data are lacking for other cytokines. The limited data for incubation of cytokine cocktails with hepatocytes suggest similar extents of CYP suppression for combined cytokines compared to IL-6 alone. In vivo data supporting a direct effect of IL-2, IL-8, IL-10, IL-17, IFN-γ, TNF-α or VEGF on CYP activity are inconclusive, and the reported interactions could be driven by increases in a range of cytokines, including IL-6. Although raised levels of IL-6, IFN-γ and/or TNF-α could lead to CYP suppression, the cytokine levels observed in common immune disorders are generally lower than the in vitro EC₅₀ values (Table 4), suggesting minimal CYP suppression in most patients. However, transiently elevated concentrations following dosing of cytokine modulators (e.g., blinatumomab) may be close to or above EC₅₀ values.

By incorporating in vitro CYP mRNA Eₘᵢₙ and EC₅₀ values of IL-6 (Dickmann et al., 2011), current PBPK models are able to predict concentrations of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 substrates in the presence of chronically raised IL-6 (Machavaram et al., 2013, 2019; Jiang et al., 2016) and concentrations of CYP2C19 and CYP3A4 substrates in the presence of transiently raised IL-6 (Xu et al., 2015; Stader et al., 2021; Lenoir et al., 2021c) with
reasonable performance (i.e., predicted-to-observed ratios of mean AUC or $C_{\text{max}} < 2$; Figure 1). There are no $E_{\text{min}}$ and $EC_{50}$ values reported for most other cytokines, hindering their inclusion in PBPK models. Here we have calculated CYP1A2 values for IFN-γ from reported in vitro hepatocyte data. $E_{\text{min}}$ and $EC_{50}$ values of TNF-α for CYP1A2, CYP2B6, CYP2C9, and CYP3A4 mRNA were also estimated, using data measured in HepaRG cells (Klein et al., 2015) but should be confirmed in human hepatocytes in future experiments.

When evaluating DBI liability, one should consider two opposite directions for the interaction. Cytokine levels can decrease due to down-regulation of the activity of proinflammatory cytokines (e.g., RA treatment), or contrarily, transiently increase due to rapid release of cytokines into the blood from immune cells (e.g., cytokine release syndrome). The former case is similar to PBPK simulation scenarios used in Machavaram et al. (2013 and 2019) and Jiang et al. (2016), whereas the latter case would be analogous to PBPK simulation scenarios in Xu et al. (2015) and Stader et al. (2021). In both cases, the risk of DBIs is generally reported to be moderate or weak in most patients (Coutant & Hall 2018) and can likely be predicted with PBPK models considering IL-6 alone, given that other cytokines are less potent CYP suppressors and circulating at concentrations much lower in diseases than those used in most in vitro incubations. While cytokines can markedly increase after cytokine modulator dosing, significant DBI is still unlikely as the elevation is transient and enzyme levels return to baseline quickly as demonstrated in the PBPK simulations. Despite the low risks, caution needs to be taken in DBI assessment for drugs with a narrow therapeutic index/low safety margins.

In conclusion, following dosing of cytokine modulating drugs the levels of multiple cytokines are likely to be increased or decreased simultaneously. The in vitro and in vivo data suggest that IL-6 is the most important cytokine when considering the effect of cytokine
modulators on small molecule drug PK, although the available data are very limited in some cases. Published PBPK models assessing the effect of IL-6 on small molecule PK can adequately predict DBIs in a range of disease states. Hence, it is likely that inclusion of other cytokines into such PBPK models is not warranted and that any DBI interactions will generally be weak.
Authorship contributions

Participated in research design: Chen, K-F, Gill, K.L., and Jones, H.M.

Conducted experiments: Chen, K-F and Gill, K.L.

Contributed new reagents or analytic tools: Chen, K-F and Gill, K.L.

Performed data analysis: Chen, K-F and Gill, K.L.

Wrote or contributed to the writing of the manuscript: Chen, K-F, Gill, K.L., and Jones, H.M.
References

Abdel-Razzak Z, Corcos L, Fautrel A, Campion JP, Guillouzo A (1994). Transforming Growth Factor-β1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. *Mol Pharmacol* 46:1100-1110.

Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993). Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. *Mol Pharmacol* 44:707-715.

Aitken AE & Morgan TM (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. *Drug Metab Dispos* 35:1687-1693.

Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005). Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. *Mediators Inflamm* 5: 273–279.

Bashier Eltayeb, L., Shams, D., Babikr, N., Madani, M., Abdelghani, S., & Ali Waggiallah, H. (2020). Serum levels of Interferon Gamma INF-γ and Interleukin 10 IL-10: an Immunological Aspect among Irritable Bowel Syndrome Patients. *Pak J Biol Sci* 23: 898–903.

Berberoglu, U., Yildirim, E., & Celen, O. (2004). Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. *Int J Biol Markers* 19: 130–134.

Lippitz, B. E., & Harris, R. A. (2016). Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. *Oncoimmunology*, 5: e1093722.
Brockmeyer NH, Mertins L, Spatz D, Tillmann I, Goos M (1992). Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. *Int J Clin Pharmacol Ther Tox* **30**: 530-533.

Brockmeyer NH, Barthel B, Mertins L, Goos M (1998). Effect of Zidovudine Therapy in Patients with HIV Infection on Endogenous Interferon Plasma Levels and the Hepatic Cytochrome P450 Enzyme System. *Chemotherapy* **44**: 174-180.

Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008). Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. *Biol Psychiatry* **63**: 1022-1029.

Caris JA, Benzi JRL, de Souza FFL, de Oliveira RDR, Donadi EA, Lanchote VL (2020). Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe. *Eur J Pharmaceut Sci* **146**: 105264.

Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, De Sousa M, Giroud JP, Flouvat B, Chauvelot-Moachon L (1994). Acute-phase response, interleuhn-6, and alteration of cyclosporine pharmacokinetics. *Clin Pharmacol Ther* **55**: 649-60.

Chung, S. J., Kwon, Y. J., Park, M. C., Park, Y. B., & Lee, S. K. (2011). The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. *Yonsei Med J* **52**: 113–120.

Coutant DE, Hall SD (2018) Disease–Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance. *J Clin Pharmacol* **58**: 849-863.
Dallas S, Sensenhauser C, Batheja A, Singer M, Markowska M, Zakszewski C, Mamidi RNVS, McMillian M, Han C, Zhou H, Silva J (2012). De-Risking Bio-therapeutics for Possible Drug Interactions Using Cryopreserved Human Hepatocytes. *Curr Drug Metab* **13**: 923-929.

de Jong, L. M., Jiskoot, W., Swen, J. J., & Manson, M. L. (2020). Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics. *Genes*, **11**: 1509.

de Oliveira, P. S., Cardoso, P. R., Lima, E. V., Pereira, M. C., Duarte, A. L., Pitta, I., Rêgo, M. J., & Pitta, M. G. (2015). IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients. *MEDIATORS INFLAMM* **2015**: 819149.

Del Giudice, M., & Gangestad, S. W. (2018). Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. *Brain Behav Immun* **70**: 61–75.

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG (2011). Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture. *Drug Metab Dispos* **39**: 1415-1422.

Dickmann LJ, Patel SK, Wienkers LC, Slatter JG (2012). Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture. *Curr Drug Metab* **13**: 930-937.

Ding, J., Su, S., You, T., Xia, T., Lin, X., Chen, Z., & Zhang, L. (2020). Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. *Clinics (Sao Paulo, Brazil)* **75**: e1801.
Donato MT, Herrero E, Gómez-Lechón MJ, Castel JV (1993). Inhibition of monooxygenase activities in human hepatocytes by interferons, *Toxicol in Vitro* 7: 481-485.

Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, and Pessayre D (1999). Decrease in Hepatic Cytochrome P450 after Interleukin-2 Immunotherapy. *Biochemical Pharmacology* 57: 951–954.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L (2013). Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper. *Drug Metab Dispos* 41:1598-1609.

Fardel, O., & Le Vée, M. (2009). Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. *Expert Opin Drug Metab Toxicol* 5: 1469–1481.

Frye RF, Schneider VM, Frye CS, Feldman AM (2002). Plasma Levels of TNF-α and IL-6 are Inversely Related to Cytochrome P450-dependent Drug Metabolism in Patients With Congestive Heart Failure. *J Cardiac Fail* 8: 315-319.

Gersku GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ (1998). A role for tumour necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. *Br J Haematol* 103: 176-188.

Godoy ALPC, Rocha A, da Silva Souza C, Lanchote VL (2016) Pharmacokinetics of Venlafaxine Enantiomers and Their Metabolites in Psoriasis Patients. *J Clin Pharmacol* 56: 567-575.
Godsell, J., Rudloff, I., Kandane-Rathnayake, R., Hoi, A., Nold, M. F., Morand, E. F., & Harris, J. (2016). Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. *Sci Rep* **6**: 34604.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. (2000). In vivo effects of interleukin-10 on human cytochrome P450 activity. *Clin Pharmacol Ther* **67**: 32-43.

Guillén MI, Donato MT, Jover R, Castel JV, Fabra R, Trullenque R, Gómez-Lechón MJ (1998). Oncostatin M Down-regulates Basal and Induced Cytochromes P450 in Human Hepatocytes. *J Pharmacol Exp Ther* **285**: 127-134.

Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD (2009). Inflammation Causes Mood Changes Through Alterations in Subgenual Cingulate Activity and Mesolimbic Connectivity. *Biol Psychiatry* **66**: 407-414.

Harvey RD & Morgan ET (2014). Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents. *Clin Pharmacol Ther* **96**: 449-457.

Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharaia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YYS, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE (2014). Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. *Hum Vaccin Immunother* **10**: 3446-3454.

Huang S-M, Zhao H, Lee J-I, Reynolds K, Zhang L, Temple R, Lesko LJ (2010). Therapeutic Protein–Drug Interactions and Implications for Drug Development. *Clin Pharmacol Ther* **87**: 497-503.
Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A (2005). Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer. *J Clin Oncol* **23**: 2544-2555.

Idborg H, Eketjäll S, Pettersson S, Gustafsson JT, Zickert A, Kvarnström M, Oke V, Jakobsson P-J, Gunnarsson I, Svenungsson E (2018). TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. *Lupus Sci Med* **5**: e000260.

Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H (2016). Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein–Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. *AAPS J* **18**: 767-776.

Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba ADM (2010). Variability in drug metabolizing enzyme activity in HIV-infected patients. *Eur J Clin Pharmacol* **66**: 475-485.

Jones, H. M., Chan, P. L., van der Graaf, P. H., & Webster, R. (2012). Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. *Br J Clin Pharmacol* **73**: 77–92.

Jonkman JH & Upton RA (1984). Pharmacokinetic Drug Interactions with Theophylline. *Clin Pharmacokinet* **9**: 309-334.

Klein M, Thomas M, Hofmann U, Seehofer D, Damm G, Zanger UM (2015). A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and
excretion gene expression and activity in primary human hepatocytes and HepaRG cells. *Drug Metab Dispos* **43**: 273-283.

Kuhlman KR, Robles TF, Dooley LN, Boyle CC, Haydon MD, Bower JE (2018). Within-subject associations between inflammation and features of depression: Using the flu vaccine as a mild inflammatory stimulus. *Brain Behav Immun* **69**: 540-547.

Lacki, J. K., Klama, K., Mackiewicz, S. H., Mackiewicz, U., & Müller, W. (1995). Circulating interleukin 10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. *Inflamm Res* **44**: 24–26.

Le Vee, M., Lecureur, V., Stieger, B., & Fardel, O. (2009). Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. *Drug Metab Dispos* **37**: 685–693.

Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, Bodrug I, Kivitz A (2017). Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. *Clin Pharmacokinet* **56**: 607-615

Lee JI, Zhang L, Men AY, Kenna LA, Huang S-M (2010). CYP-Mediated Therapeutic Protein-Drug Interactions, Clinical Findings, Proposed Mechanisms and Regulatory Implications. *Clin Pharmacokinet* **49**: 295-310.

Lee K-S, Chung W-Y, Park J-E, Jung Y-J, Park J-H, Sheen S-S, Park K-J (2021). Interferon-γ-Inducible Chemokines as Prognostic Markers for Lung Cancer. *IRJPEH* **18**: 9345.

Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, Walder B, Gabay C, Nissen MJ, Desmeules JA, Hannouche D, Samer CF (2021a). Impact of Acute Inflammation on
Cytochromes P450 Activity Assessed by the Geneva Cocktail. *Clin Pharmacol Ther* **109**: 1668-1676.

Lenoir, C., Terrier, J., Gloor, Y., Curtin, F., Rollason, V., Desmeules, J. A., Daali, Y., Reny, J. L., & Samer, C. F. (2021). Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. *Clinical Pharmacol Ther* **110**: 1358–1367.

Lenoir, C., Niederer, A., Rollason, V., Desmeules, J. A., Daali, Y., & Samer, C. F. (2022). Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. *CPT Pharmacometrics Syst Pharmacol* **11**: 30–43.

Lévesque, E., Beaulieu, M., Guillemette, C., Hum, D. W., & Bélanger, A. (1998). Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. *Endocrinology*, **139**: 2375–2381.

Li AP, Yang Q, Vermet H, Raoust N, Klieber S, Fabre G (2014). Evaluation of Human Hepatocytes Under Prolonged Culture in a Novel Medium for the Maintenance of Hepatic Differentiation: Results with the Model Pro-inflammatory Cytokine Interleukin 6. *Drug Metab Lett* **8**: 12-18.

Li, S., Fu, X., Wu, T., Yang, L., Hu, C., & Wu, R. (2017). Role of Interleukin-6 and Its Receptor in Endometriosis. *Med Sci Monit* **23**: 3801–3807.

Lin S, Henning AK, Akhlaghi F, Reisfield R, Vergara-Silva A, and First MR (2015) Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation. *Ther Drug Monit* **37**: 206-213.
Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR (2013). A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6. *Clin Pharmacol Ther* **94**: 260-268.

Machavaram KK, Endo-Tsukude C, Terao K, Gill KL, Hatley OJ, Gardner I, Parrott N, Ducray PS (2019). Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. *AAPS J* **21**: 42.

Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, Hollinger A, Osthoff M, Weisser M, Gebhard CE, Baettig V, Geenen J, Khanna N, Tschudin-Sutter S, Mueller D, Hirsch HH, Battegay M, Sendi P (2020). Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. *Antimicrob Agents Chemother* **64**: e01177-20.

Mimura H, Kobayashi K, Xu L, Hashimoto M, Ejiri Y, Hosoda M, Chiba K (2015). Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the threedimensionally cultured human hepatoma cell line FLC-4. *Drug Metab Pharmacokinet* **30**: 105-110.

Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008). Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer. *Drug Metab Dispos* **36**: 205-216.

Mortaz, E., Bassir, A., Dalil Roofchayee, N., Dezfuli, N. K., Jamaati, H., Tabarsi, P., Moniri, A., Rezaei, M., Mehrian, P., Varahram, M., Marjani, M., Mumby, S., & Adcock, I. M. (2021).
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. *Int Immunopharmacol* **93**: 107407.

Oke, V., Gunnarsson, I., Dorschner, J. *et al.* (2019) High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. *Arthritis Res Ther* **21**: 107.

Pellegrino P, Clementi E, Capuano A, Radice S (2015). Can vaccines interact with drug metabolism? *Pharmacol Res* **92**:13-17.

Piscitelli SC, Vogel S, Figg WD, Raje S, Forrest A, Metcalf JA, Baseler M, and Falloon J. (1998) Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. *Pharmacother* **18**: 1212-1216.

Podgaec, S., Abrao, M. S., Dias, J. A., Jr, Rizzo, L. V., de Oliveira, R. M., & Baracat, E. C. (2007). Endometriosis: an inflammatory disease with a Th2 immune response component. *Hum Reprod* **22**: 1373–1379.

Rana, S. V., Sharma, S., Sinha, S. K., Parsad, K. K., Malik, A., & Singh, K. (2012). Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. *Trop Gastroenterol* **33**: 251–256.

Richardson, T. A., Sherman, M., Kalman, D., & Morgan, E. T. (2006). Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney. *Drug Metab Dispos* **34**: 351–353.
Roh, N. K., Han, S. H., Youn, H. J., Kim, Y. R., Lee, Y. W., Choe, Y. B., & Ahn, K. J. (2015). Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison between Plaque and Guttate Psoriasis. *Ann Dermatol* **27**: 738–743.

Rubin K, Janefeldt A, Andersson L, Berke Z, Grime K, Andersson TB (2015). HepaRG Cells as Human-Relevant In Vitro Model to Study the Effects of Inflammatory Stimuli on Cytochrome P450 Isoenzymes. *Drug Metab Dispos* **43**: 119-125.

Sato H, Naito T, Ishida T, Kawakami J (2016). Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients. *Eur J Clin Pharmacol* **72**: 1463-1470.

Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011). Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis. *Clin Pharmacol Ther* **89**: 735-740.

Sharpley AL, Cooper CM, Williams C, Godlewska BR, Cowen PJ (2016). Effects of typhoid vaccine on inflammation and sleep in healthy participants: a double-blind, placebo-controlled, crossover study. *Psychopharmacology (Berl).* **233**: 3429-3435.

Sifontis NM, Benedetti E, and Vasquez EM (2002) Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. *Transplant Proc* **34**: 1730-1732.

Simon F, Gautier-Veyret E, Truffot A, Chenel M, Payen L, Stanke-Labesque F, Tod M (2021). Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates. *Pharm Res* **38**: 415-428.
Sobhan, M. R., Farshchian, M., Hoseinzadeh, A., Ghasemibasir, H. R., & Solgi, G. (2016). Serum Levels of IL-10 and IL-22 Cytokines in Patients with Psoriasis. *Iran J Immunol* **13**: 317–323.

Stader F, Battegay M, Sendi P, Marzolini C (2021). Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. *Clin Pharmacol Ther* **111**: 579-584.

Strehlau J, Pape L, Offner G, Nashan B, and Ehrich JH (2000) Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. *Lancet* **356**: 1327-1328.

Sunman JA, Hawke RL, LeCluyse EL, Kashuba ADM (2004). Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. *Drug Metab Dispos* **32**: 359-363.

Terao KT, Tsuru T, Suzaki M, Ishida Y, Amamoto T, Amamoto H, Higuchi S, Nishimoto N (2010). Drug–disease interaction study of tocilizumab in patients with rheumatoid arthritis—IL-6 signal inhibition normalised cytochrome P-450 enzymes expression which was reduced by inflammation. *Int J Rheum Dis* **13**: 95-105.

Thilagar, S., Theyagarajan, R., Sudhakar, U., Suresh, S., Saketharaman, P., & Ahamed, N. (2018). Comparison of serum tumor necrosis factor-α levels in rheumatoid arthritis individuals with and without chronic periodontitis: A biochemical study. *J Indian Soc Periodontol* **22**: 116–121.

Trousil S, Lee P, Edwards RJ, Maslen L, Lozan-Kuehne JP, Ramaswami R, Aboagye EO, Clarke S, Liddle C, Sharma R (2019). Altered cytochrome 2E1 and 3A P450-dependent drug
metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. *Br J Pharmacol* **176**: 3712-3722.

Tsai MY, Hanson NQ, Straka RJ, Hoke TR, Or dovas JM, Peacock JM, Arends VL, Arnett DK (2005). Effect of influenza vaccine on markers of inflammation and lipid profile. *J Lab Clin Med* **145**: 323-327.

U.S. Food and Drug Administration. (2022). Drug-drug interaction assessment for therapeutic proteins. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry.

Wienkers, L. C., & Heath, T. G. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. *Nat Rev Drug Discov* **4**: 825–833.

Wen H, Chen D, Lu J, Jiao Z, Chen B, Zhang B, Ye C, Liu L (2020) Probable Drug Interaction Between Etanercept and Cyclosporine Resulting in Clinically Unexpected Low Trough Concentrations: First Case Report. *Front Pharmacol* **11**: 939.

Wright CE, Strike PC, Brydon L, Steptoe A (2005). Acute inflammation and negative mood: Mediation by cytokine activation. *Brain Behav Immunity* **19**: 345-350.

Xu Y, Hijazi Y, Wolf A, Wu B, Sun Y-N, Zhu M (2015). Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. *CPT Pharmacometrics Syst Pharmacol* **9**: 507-515.
Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* **138**: 103–141.

Zhang XSC, Grange S, Terao K, Miya K, Kivitz A, Marino M (2009). Disease–drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo. *Clin Pharmacol Ther* **85**: S59.

Zhou H, Parks V, Patat A, Le Coz F, Simcoe D, Korth-Bradley J (2004a). Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin. *J Clin Pharmacol* **44**: 1244-1251.

Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J (2004b). Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin. *J Clin Pharmacol* **44**: 543-550.

Zhuang Y, de Vries DE, Xu Z, Marciniak Jr SJ, Chen D, Leon F, Davis HM, Zhou H (2015). Evaluation of Disease-Mediated Therapeutic Protein–Drug Interactions Between an Anti–Interleukin-6 Monoclonal Antibody (Sirukumab) and Cytochrome P450 Activities in a Phase 1 Study in Patients With Rheumatoid Arthritis Using a Cocktail Approach. *J Clin Pharmacol* **55**: 1386-1394.
Funding:

We received no funding for this work.

Conflict of Interest:

No author has an actual or perceived conflict of interest with the contents of this article. All authors are employees of Certara and hold stock in the company.
Figure Legends

Figure 1. Summary of observed and simulated effects of chronic and transient IL-6 elevation using PBPK modeling. Data extracted from Machavaram et al. (2019) (steady-state IL-6 = 50 or 100 pg/mL), Jiang et al. (2016) (steady-state IL-6 = 50 pg/mL), Xu et al. (2015) (peak IL-6 = 1600 pg/mL) and Stader et al. (2021) (peak IL-6 = 50000 pg/mL). Black and blue bars represent predicted and observed data, respectively. White, yellow, pink and red areas represent insignificant, weak, moderate and strong interaction, respectively. The observed data included in the Machavaram and Jiang papers were from the same sources (Schmitt et al., 2011, Zhang et al., 2009 and Zhuang et al., 2015).
### Tables

**Table 1. CYP mRNA or activity percent decrease measured in cryopreserved human hepatocytes incubated with IL-2 or IL-6.**

|                   | % decrease by IL-2 | % decrease by IL-6 | % decrease by IL-2 / % decrease by IL-6<sup>a</sup> |
|-------------------|--------------------|--------------------|---------------------------------------------------|
| CYP2B6 activity   | 21                 | 30                 | 0.70                                              |
| CYP2C19 activity  | 22                 | 65                 | 0.34                                              |
| CYP2D6 activity   | 22                 | 39                 | 0.56                                              |
| CYP2D6 mRNA       | 1.5                | 2.4                | 0.63                                              |

Data extracted from Dallas et al., 2012; n = 3 donors, treated with 10 ng/mL IL-2 or IL-6 for 48 h. <sup>a</sup> The ratios compare the extent of suppression by IL-2 relative to IL-6.
Table 2. CYP mRNA, protein expression or activity percent decrease measured in primary human hepatocytes treated with IFN-γ or IL-6.

| Measure | % decrease by IFN-γ | % decrease by IL-6 | % decrease by INF-γ / % decrease by IL-6 | Study |
|---------|---------------------|---------------------|------------------------------------------|-------|
| EROD activity (mainly CYP1A2) | 40 28 | 1.44 | | Abdel-Razzak et al., 1993 |
| CYP1A2 activity | 53 36 | 1.47 | | Guillén et al., 1998 |
| CYP1A2 mRNA | 18 24 | 0.75 | | Abdel-Razzak et al., 1993 |
| CYP2C8 mRNA | 48 54 | 0.89 | | Aitken and Morgan, 2007 |
| CYP2C9 mRNA | NS 34 | - | | Aitken and Morgan, 2007 |
| CYP2C9 protein | 67 88 | 0.76 | | Aitken and Morgan, 2007 |
| CYP2C18 mRNA | NS 26 | - | | Aitken and Morgan, 2007 |
| CYP2C19 mRNA | NS 37 | - | | Aitken and Morgan, 2007 |
| CYP2B6 activity | 48 47 | 1.03 | | Guillén et al., 1998 |
| CYP2B6 mRNA | 74 78 | 0.95 | | Aitken and Morgan, 2007 |
| CYP2B6 protein | 40 62 | 0.65 | | Aitken and Morgan, 2007 |
| CYP3A4 activity | 34 19 | 1.80 | | Guillén et al., 1998 |
| CYP3A4 mRNA | 77 95 | 0.80 | | Aitken and Morgan, 2007 |
| CYP3A mRNA | NS 53 | - | | Abdel-Razzak et al., 1993 |
| CYP3A4 protein | 54 45 | 1.19 | | Aitken and Morgan, 2007 |
| CYP2E1 mRNA | 39 53 | 0.74 | | Abdel-Razzak et al., 1993 |

n = 1 - 11 donor. In Abdel-Razzak et al. (1993) and Abdel-Razzak et al. (1994), primary human hepatocytes were treated with 50 U/mL IFN-γ or 50 U/mL IL-6 for 72 h. In Guillén et al. (1998), primary human hepatocytes were treated with 300 U/mL IFN-γ or 100 U/mL IL-6 for 24 h. In Aitken and Morgan (2007), primary human hepatocytes were treated with 10 ng/mL IFN-γ or 10 ng/mL IL-6 for 24 h. NS = no significant change. * The ratios compare the extent of suppression by INF-γ relative to IL-6.
Table 3. CYP mRNA, protein expression or activity percent decrease measured in primary human hepatocyte cultures treated with TNF-α or IL-6.

| Measure          | % decrease by TNF-α | % decrease by IL-6 | % decrease by TNF-α / % decrease by IL-6 | Study                  |
|------------------|---------------------|-------------------|------------------------------------------|------------------------|
| CYP1A2 activity  | 72                  | 23                | 3.13                                     | Dallas et al., 2012    |
| CYP1A2 activity  | 57                  | 28                | 2.04                                     | Abdel-Razzak et al., 1993 |
| CYP1A2 mRNA      | 73                  | 24                | 3.09                                     | Abdel-Razzak et al., 1993 |
| CYP1A2 mRNA      | 45                  | 15                | 3.00                                     | Dallas et al., 2012    |
| CYP2B6 activity  | 35                  | 30                | 1.17                                     | Dallas et al., 2012    |
| CYP2B6 mRNA      | NS                  | 78                | -                                        | Aitken & Morgan, 2007  |
| CYP2B6 mRNA      | NS                  | 63                | -                                        | Dallas et al., 2012    |
| CYP2B6 protein   | 59                  | 62                | 0.95                                     | Aitken & Morgan, 2007  |
| CYP2C8 mRNA      | 64                  | 54                | 1.17                                     | Aitken & Morgan, 2007  |
| CYP2C9 activity  | 16                  | 35                | 0.47                                     | Dallas et al., 2012    |
| CYP2C9 mRNA      | NS                  | 34                | -                                        | Aitken & Morgan, 2007  |
| CYP2C9 mRNA      | NS                  | 63                | -                                        | Dallas et al., 2012    |
| CYP2C9 protein   | 94                  | 88                | 1.07                                     | Aitken & Morgan, 2007  |
| CYP2C19 activity | 84                  | 65                | 1.29                                     | Dallas et al., 2012    |
| CYP2C19 mRNA     | NS                  | 37                | -                                        | Aitken & Morgan, 2007  |
| CYP2C19 mRNA     | NS                  | 72                | -                                        | Dallas et al., 2012    |
| CYP2D6 activity  | 45                  | 39                | 1.15                                     | Dallas et al., 2012    |
| CYP2D6 mRNA      | 46                  | -240              | opposite direction                       | Dallas et al., 2012    |
| CYP2E1 mRNA      | 44                  | 52                | 0.84                                     | Abdel-Razzak et al., 1993 |
| CYP3A4 activity  | 70                  | 76                | 0.92                                     | Dallas et al., 2012    |
| CYP3A4 activity  | 60                  | 38                | 1.58                                     | Abdel-Razzak et al., 1993 |
| CYP3A4 activity  | NS                  | 69                | -                                        | Mimura et al., 2015    |
| CYP3A4 mRNA      | 58                  | 53                | 1.10                                     | Abdel-Razzak et al., 1993 |
| CYP3A4 mRNA      | 81                  | 95                | 0.85                                     | Aitken & Morgan, 2007  |
| CYP3A4 mRNA      | 85                  | 98                | 0.87                                     | Dallas et al., 2012    |
| CYP3A4 mRNA      | 61                  | 78                | 0.78                                     | Mimura et al., 2015    |
| CYP3A4 protein   | NS                  | 45                | -                                        | Aitken & Morgan, 2007  |
n = 1 - 9 donors. In Dallas et al. (2012), cryopreserved human hepatocytes were treated with 10 ng/mL TNF-α or 10 ng/mL IL-6 for 48 h. In Abdel-Razzak et al. (1993), primary human hepatocytes were treated with 50 U/mL TNF-α or 50 U/mL IL-6 for 72 h. In Aitken and Morgan (2007), primary human hepatocytes were treated with 10 ng/mL TNF-α or 10 ng/mL IL-6 for 24 h. In Mimura et al. (2015), primary human hepatocytes were treated with 10 ng/mL TNF-α or 10 ng/mL IL-6 for 48 h. NS = no significant change. a The ratios compare the extent of suppression by TNF-α relative to IL-6.
Table 4. Calculated and reported $E_{\text{min}}$ and $EC_{50}$ values of IL-6, IFN-γ and TNF-α for different CYP isoforms

| Measure       | System         | Cytokine | Incubation concentration (pg/mL) | Incubation time (h) | $E_{\text{min}}$ (fold) | $EC_{50}$ (pg/mL) | $E_{\text{min}} \times EC_{50}$ | Study                  |
|---------------|----------------|----------|----------------------------------|---------------------|--------------------------|-------------------|-------------------------------|------------------------|
| CYP1A2 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.157                    | 271               | 42.5                          | Dickman et al., 2011  |
| CYP1A2 mRNA   | HepaRG cells    | TNF-α    | 0.1 – 50000                      | 24                  | 0.0337                   | 817               | 27.5                          | Klein et al., 2015    |
| CYP2B6 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.0311                   | 70                | 2.18                          | Dickman et al., 2011  |
| CYP2B6 mRNA   | HepaRG cells    | TNF-α    | 0.1 – 50000                      | 24                  | 0.639                    | 86.6              | 55.3                          | Klein et al., 2015    |
| CYP2C19 mRNA  | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.214                    | 71.3              | 15.3                          | Dickman et al., 2011  |
| CYP2C8 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.0386                   | 153               | 5.91                          | Dickman et al., 2011  |
| CYP2C9 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.0525                   | 121               | 6.35                          | Dickman et al., 2011  |
| CYP2C9 mRNA   | HepaRG cells    | TNF-α    | 0.1 – 50000                      | 24                  | 0.289                    | 153               | 44.3                          | Klein et al., 2015    |
| CYP2D6 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.302                    | 151               | 45.6                          | Dickman et al., 2011  |
| CYP3A4 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.00                     | 3.23              | 0.00                          | Dickman et al., 2011  |
| CYP3A4 mRNA   | HepaRG cells    | TNF-α    | 0.1 – 50000                      | 24                  | 0.107                    | 133               | 14.2                          | Klein et al., 2015    |
| CYP3A5 mRNA   | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.0343                   | 51                | 1.75                          | Dickman et al., 2011  |
| CYP1A2 activity | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.241                    | 73.2              | 17.6                          | Dickman et al., 2011  |
| CYP1A2 activity | Human hepatocyte | IFN-γ    | 500 - 150000                     | 24                  | 0.629                    | 2460              | 1547                          | Donato et al., 1993  |
| CYP1A2 activity | Human hepatocyte | IFN-γ    | 1500 - 50000                     | 24                  | 0.572                    | 4400              | 2517                          | Donato et al., 1997  |
| CYP1A2 activity | Human hepatocyte | IFN-γ    | 2500 - 50000                     | 24                  | 0.601                    | 4098              | 2463                          | Guillén et al., 1998 |
| CYP3A4 activity | Human hepatocyte | IL-6     | 5 - 50000                        | 72                  | 0.23                     | 1251              | 288                           | Dickman et al., 2011  |

IFN-γ and TNF-α data were digitalized from the figures in the publications; subsequently, $E_{\text{min}}$ and $EC_{50}$ values were estimated using a 4-parameter fit.
